Contineum Therapeutics Inc. (CTNM)
CTNM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1855175/000143774925006458/0001437749-25-006458-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CTNM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001855175 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$42.3M |
| Operating income | -$50.9M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $21.9M |
| Total assets | $212.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $75.2M cash; operating cash flow -$13.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 39,265,813 (2026-10-30). | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 1 at the market | Latest 2026-03-05 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$18.7M | -$11.1M | $75.2M | No debt tags | Needs four quarters | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | Not filed | -$15.2M | -$11.5M | $14.7M | No debt tags | Needs four quarters | 10-Q 2026-11-03 |
| Q1 2026 2026-03-31 | Not filed | -$14.5M | -$16.3M | $20.2M | No debt tags | Needs four quarters | 10-Q 2026-11-03 |
| Q4 2025 2025-12-31 | Not filed | -$15.2M | -$13.0M | $75.6M | No debt tags | Needs four quarters | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | Not filed | -$12.8M | -$12.2M | $42.6M | No debt tags | Needs four quarters | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | Not filed | -$16.0M | -$15.7M | $20.8M | No debt tags | Needs four quarters | 10-Q 2026-11-03 |
| Q1 2025 2025-03-31 | Not filed | -$16.0M | -$14.4M | $22.5M | No debt tags | Needs four quarters | 10-Q 2026-11-03 |
| Q4 2024 2024-12-31 | $0 | -$14.6M | -$10.2M | $21.9M | No debt tags | $0 | 10-K 2025-03-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-03-05 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 204 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.6% |
| 1 month | +17.1% |
| 3 months | -35.6% |
| Year to date | -13.7% |
| 1 year | -9.5% |
| From 52-week high | -43.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PBYI | Puma Biotechnology Inc | $7.34 | -5.53% | $379.5M |
| CRMD | CorMedix Inc. | $4.82 | +3.43% | $383.4M |
| RLMD | Relmada Therapeutics Inc. | $3.61 | -14.25% | $385.2M |
| IRD | Opus Genetics Inc. | $4.04 | +1.51% | $390.5M |
| PEPG | PepGen Inc. | $4.19 | -3.90% | $395.0M |
| SPRY | ARS Pharmaceuticals Inc. | $3.59 | -7.71% | $360.9M |
| ASPE | Aspen Neuroscience Inc. | $12.23 | -2.86% | $355.6M |
| PRTA | Prothena Corporation plc | $7.97 | -2.33% | $409.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier